Arrowhead Pharmaceuticals, Inc. is a US-based drug development company that focuses on treating intractable diseases. They have multiple products in development, including ARO-AAT for liver diseases, ARO-APOC3 for hypertriglyceridemia, ARO-COV for COVID-19, and more. Arrowhead has partnerships with Janssen Pharmaceuticals and Takeda Pharmaceuticals to develop RNAi therapeutics for liver disease targets.